Investors

Teligent is a specialty generic pharmaceutical company (NASDAQ: TLGT). Our mission is to be a leading player in the specialty generic prescription drug market.

We currently have 22 Abbreviated New Drug Applications (ANDAs) on file at the FDA, representing a total addressable market of approximately $1.6 billion (IQVIA, June 2018).

We sell a portfolio of prescription topical medicines and a growing number of hospital-based sterile injectable products, including cephalosporins.

"As we execute our strategy, our focus is to scale up and strengthen our business, so we can deliver sustained financial performance."

Damian Finio
CFO

Recent News

Teligent, Inc. Announces FDA Approval of Fluocinonide Topical Solution USP, 0.05%

BUENA, N.J. , March 19, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic ph...

Learn More

Teligent, Inc. Announces Fourth Quarter and Year End 2018 Results

BUENA, N.J. , March 18, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic ph...

Learn More

Teligent, Inc. to Present at the 31st Annual ROTH Conference Tuesday March 19, 2019

BUENA, N.J. , March 15, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pha...

Learn More

Stock Information

Copyright West LLC. Minimum 15 minutes delayed.


Events

Investor Overview

There are no items to display.